Ingevity zvýšila výhled upraveného EBITDA na rok 2026 na 380–400 mil. USD poté, co její upravený zisk EBITDA ve druhém čtvrtletí vzrostl ze 101 mil. USD na 115 mil. USD.
Key Takeaways NGVT's Q2 adjusted EBITDA rose to $115 million from $101 million, with its margin reaching 36.6%.Higher pricing, favorable product mix, improved asset utilization and increased volumes drove NGVT's growth.NGVT raised its 2026 adjusted EBITDA guidance to $380-$400 million and adjusted EPS outlook to $5-$5.45. Ingevity Corporation (NGVT - Free Report) reported an adjusted EBITDA of $115 million in the second quarter, up from the prior-year quarter’s $101 million. This was supported by higher prices, favorable product mix, and increased volumes in Performance Materials and Pavement Technologies, along with improved product mix and asset utilization in Advanced Polymer Technologies.
NGVT also outdid its last year’s second-quarter adjusted EBITDA margin by 6.1%, with second-quarter 2026 adjusted EBITDA margin reaching 36.6%. The company’s efforts to strengthen commercial and operational execution keep its profitability positioned for further improvement.
The actions for its portfolio transformation are underway, particularly the divestiture of the Road Markings segment and directing resources towards higher-return opportunities, which favor the company in the long run. With a more focused company and differentiated technology, Ingevity is poised for higher organic growth opportunities that ensure lucrative returns. Its first municipal water-treatment contract for PFAS filtration is also a growth driver.
The expectation of continued strength in adjusted EBITDA generation is also underlined by the company’s raised guidance released in the second-quarter earnings call. The company increased its 2026 adjusted EBITDA forecast to $380-$400 million from $370-$395 million. A raised full-year 2026 adjusted earnings guidance to $5-$5.45 per share from the previous projection of $4.7-$5.2 also reinforces NGVT’s expectations of higher growth.
Among its peers, Cabot Corporation (CBT - Free Report) generated a relatively lower adjusted EBITDA of $194 million in the third quarter of fiscal 2026 compared with $211 million in the year-ago quarter. The company’s Performance Chemicals segment aided the performance through higher volumes and expanded unit margins. Cabot is also preparing itself to support higher global battery demand by targeting additive capacity investments in both the United States and China. For fiscal 2026, Cabot tightened its adjusted earnings guidance to $6.15-$6.45 per share from the previous range of $6-$6.5.
Element Solutions Inc. (ESI - Free Report) recorded second-quarter adjusted EBITDA of roughly $184 million, up from the previous-year quarter’s $136 million. As the company is favored by a healthy core market, its own efforts to improve operational excellence complement its growth in profits. ESI now expects adjusted EBITDA for the fiscal year 2026 to be in the range of $690-$710 million, revised upwards from its previous projection of $665-$685 million.
The Zacks Rundown for NGVTShares of NGVT have gained 26.3% in the past year against the Zacks Chemical - Specialty industry’s rise of 4.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, NGVT is currently trading at a forward price-to-sales multiple of 2.1, a discount to the industry average of 2.45X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for NGVT’s 2026 and 2027 earnings implies a year-over-year rise of 30.75% and 9.26%, respectively. The EPS estimates for 2026 and 2027 have been trending higher over the past 90 days.
NGVT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ingevity za poslední rok posílila o 33,9 % díky transformaci portfolia a kapitálové disciplíně; do roku 2027 plánuje odkoupit akcie za 300 milionů USD.
Key Takeaways Ingevity shares benefitted as portfolio transformation and disciplined capital allocation paid off.NGVT is focusing on high-return markets while targeting $300 million in share repurchases through 2027.Ingevity faces APT weakness, macro uncertainty and risks from softer North American auto production. Ingevity Corporation (NGVT - Free Report) shares have surged 33.9% in the past year on the back of disciplined capital allocation paired with the transformation of its business mix. Meanwhile, a weak demand scenario and changing customer preferences pose uncertainty, along with geopolitical uncertainties. The Zacks Chemical - Specialty industry declined 0.3% during the same period.
Image Source: Zacks Investment Research
Let’s find out why NGVT stock is worth retaining at the moment.
Portfolio Transformation and Capital Allocation Strengthen GrowthIngevity’s ongoing portfolio transformation strategy is improving its business mix with the divestitures of Industrial Specialties and Road Markings and the advanced-stage sale process for APT, allowing the company to focus on higher-return opportunities. The company has also reduced approximately $10 million of stranded costs tied to the divestitures.
Strategic acquisitions, including Georgia-Pacific’s pine chemicals business, Capa and Ozark Materials, are supporting optimization of manufacturing processes and lowering logistics costs. The new technology platforms strengthen position in the end markets. Meanwhile, new growth opportunities in PFAS filtration, European biofuels and capacity expansions across fatty acids, caprolactone and polyols provide additional avenues for growth. Strong cash flow generation is further supporting shareholder returns, with leverage reducing to 2.5X and the company targeting a $300 million share repurchase through 2027.
APT Weakness and Macro Risks Weigh on OutlookIngevity continues to face significant challenges in its APT business, where weak customer demand, China-related sales pressure, unfavorable pricing and low plant utilization are weighing on profitability. The company also faced significant impairment charges last year, including goodwill impairment in APT, reinforcing the need for its planned divestiture.
Broader macroeconomic uncertainty, such as tariffs, higher raw material, logistics and energy costs and geopolitical volatility could pressure demand. In addition, weaker North American auto production, particularly in the second half of 2026, could pressure Performance Materials, while the segment remains exposed to uncertainty surrounding hybrid and ICE demand, EV adoption, government incentives and changing consumer preferences.
NGVT’s Zacks Rank & Key PicksNGVT currently carries a Zacks Rank #3 (Hold)
Some better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Air Products and Chemicals, Inc. (APD - Free Report) and Avient Corporation (AVNT - Free Report) .
RS, APD and AVNT each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.23 per share, indicating a 62.9% year-over-year increase. RS’shares have gained 42.8% over the past year.
The Zacks Consensus Estimate for APD’s fiscal 2026 earnings is pegged at $13.46 per share, indicating a rise of 11.9% year over year. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 2.9%.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 29.2% over the past year.
Ingevity za poslední rok stoupla o 30,6 % díky transformaci portfolia, vyššímu peněžnímu toku a snižování dluhu. Ve 2. čtvrtletí dosáhl volný peněžní tok asi 89 milionů USD a zadlužení kleslo na 2,5x.
Key Takeaways Ingevity's portfolio transformation through divestitures and acquisitions is reshaping its growth strategy.NGVT's cash flow gains and debt reduction lowered leverage to 2.5X while supporting capital returns.Ingevity sees growth opportunities from PFAS contracts, biofuels applications and capacity expansions. Ingevity Corporation’s (NGVT - Free Report) shares have rallied 30.6% in the past year. The company has also outperformed the Zacks Chemical - Specialty industry’s 0.2% growth over the same time frame. Ingevity’s portfolio optimization actions, investments in capacity and debt reduction supported by higher cash flows have boosted investor confidence in its long-term growth prospects.
Image Source: Zacks Investment Research
Let’s take a look at the factors that are driving NGVT stock.
Portfolio Transformation and New Growth OpportunitiesIngevity has been benefiting from its portfolio transformation strategy, supported by strategic divestitures, acquisitions and successful repositioning efforts. The divestiture of the Industrial Specialties business and Road Markings product line, along with the ongoing sale process for the APT business, is optimizing the company’s portfolio and increasing focus on higher-return opportunities.
The elimination of $10 million of stranded costs and acquisitions of Georgia-Pacific’s pine chemicals business, Capa caprolactone business and Ozark Materials are further strengthening the portfolio through manufacturing optimization, lower logistics costs, new technology platforms and more market opportunities. Meanwhile, PFAS filtration contract, European biofuels applications for TOFA and capacity expansions in soy-based fatty acids, caprolactone and polyols are creating opportunities for long-term growth.
Cash Flow and Capital Allocation Support ReturnsImproving cash generation and disciplined capital allocation have also supported Ingevity’s performance. In the second quarter, free cash flow excluding the litigation settlement payment reached approximately $89 million, while debt reduction lowered leverage to 2.5X. The company’s focus on further reducing leverage to 2X-2.5X, alongside the plan to repurchase $300 million of shares through 2027, underscores its commitment to strengthening the balance sheet while returning capital to shareholders.
NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Avient Corporation (AVNT - Free Report) and Kronos Worldwide, Inc. (KRO - Free Report) .
AVNT sports a Zacks Rank #1 (Strong Buy) at the moment, while RS and KRO carry a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $22.53 per share, indicating a 58% year-over-year increase. RS’shares have gained 36.7% over the past year.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 27.3% over the past year.
The Zacks Consensus Estimate for KRO’s 2026 earnings is pegged at 35 cents per share, indicating a rise of 136.5% year over year. KRO’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 34%.
Ingevity dokončuje přestavbu portfolia a soustředí se na Performance Materials a Pavement Technologies. Firma zároveň hledá růst ve filtraci PFAS a v teplé asfaltové směsi.
Ingevity NYSE: NGVT is nearing completion of a strategic portfolio transformation that has narrowed its focus to its Performance Materials and Pavement Technologies businesses, President and Chief Executive Officer David Li said during a Water Tower Research conference session.
Li, who became CEO in April of the prior year, said the company reviewed its portfolio to identify core competencies and made decisions to exit noncore operations. At its investor day in December, Ingevity announced plans to divest three businesses. Li said two of those divestitures have been completed, while the remaining Advanced Polymer Technologies business is in advanced stages of the sale process.
Get Ingevity alerts:
The company has also focused on strengthening its balance sheet through cash generation, debt repayment and share repurchases. Li said Ingevity reduced leverage from nearly 4 times to about 2.5 times, placing it within the company’s stated target range of 2 to 2.5 times.
Performance Materials sees hybrid and filtration opportunities Performance Materials remains Ingevity’s largest and highest-margin segment. Li described the business as a supplier of advanced carbon solutions for automotive emissions-control applications, saying the company is benefiting from consumer demand for hybrid vehicles.
While hybrid vehicles may use less carbon content than conventional internal-combustion-engine vehicles, Li said they require more advanced solutions to manage evaporative emissions. That creates a higher-value product mix for Ingevity. He said industry analysts, including S&P, have characterized the hybrid shift as structural and sustainable.
Li said the automotive business is supported by long customer qualification processes, stringent quality requirements and continued product development. He noted that Ingevity’s products have not had a recall and that the components represent a relatively small cost within a vehicle while serving regulatory and lifetime-performance requirements.
The company is also targeting water filtration as a growth avenue. Li said Ingevity recently secured its first municipal PFAS water-treatment win, with the customer selecting the company based on technology rather than the lowest bid.
Ingevity’s powdered activated carbon is designed to help filter larger PFAS molecules, including PFOA and PFOS, which Li said are expected to be included in reporting by U.S. municipalities beginning next year. He said the product can be added to existing municipal treatment operations without requiring significant capital investment.
Rather than displacing automotive production, Li said filtration could initially improve utilization of excess activated-carbon capacity. Historically, the company has sold some excess volume into other applications, primarily filtration, at nearly zero margin. Targeting higher-value filtration applications such as PFAS treatment, food and beverage, and biopharma and pharmaceutical uses could lift both segment EBITDA dollars and EBITDA margin percentage, according to Li.
Pavement Technologies targets wider warm-mix adoption In Pavement Technologies, Li identified warm-mix asphalt additives as a key growth driver. The additives are intended to help asphalt producers and paving contractors produce and place asphalt at lower temperatures, with potential benefits including longer road life, reduced pollution, lower energy costs and an extended paving season.
Li said the additives can be incorporated into existing asphalt-making processes without significant additional capital spending. He estimated that warm-mix technology has penetrated about 20% of the U.S. asphalt market, leaving room for broader adoption.
Ingevity is the market leader in the warm-mix additive category, Li said. The company is promoting the technology’s road-life and environmental benefits to transportation departments, while emphasizing longer paving seasons and energy savings for paving contractors. He said the business reported growth in the latest quarter despite higher oil prices, which raised asphalt costs and pressured project activity.
Longer-term energy storage investments and capital allocation Li said Ingevity’s investments in energy storage are longer-term opportunities and were not included in the company’s financial outlook for 2026 and 2027 presented at its investor day.
An investment in Nexeon, a developer of silicon-anode technology, could position Ingevity to supply activated carbon and operational expertise over time. A licensing agreement with CHASM is intended to support production of carbon nanotubes in North America, where Li said there is not currently a volume-capable U.S. supplier. The company is also pursuing internal innovation in areas including hard carbon. On capital allocation, Li said Ingevity expects to prioritize investments that accelerate organic growth in filtration, energy storage and Pavement Technologies. He said acquisitions are not a near-term capital-allocation priority, though bolt-on deals could become relevant over the medium to longer term, particularly in filtration.
Li said investors can monitor completion of the portfolio transformation, continued hybrid-vehicle adoption, additional filtration wins and the conversion of hot-mix asphalt demand to warm-mix applications as signs of strategy execution.
About Ingevity (NYSE:NGVT)Ingevity Corporation NYSE: NGVT is a specialty chemicals and materials company that develops products designed to improve performance, sustainability and resource efficiency across a range of industrial and consumer applications. Its businesses serve automotive, infrastructure, industrial, agricultural and other end markets.
The company's portfolio includes activated carbon products used in vehicle evaporative-emissions control systems, industrial air and water purification, and other filtration applications.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Ingevity Right Now?Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Key Takeaways Ingevity shares are up 19.2% YTD, supported by portfolio optimization and stronger hybrid demand. Adjusted EBITDA rose 14% to $115 million in Q2, while margin expanded to 36.6%.Ingevity raised 2026 adjusted EBITDA guidance to $380-$400 million amid improved earnings. Ingevity Corporation (NGVT - Free Report) shares have rallied 19.2% year to date. The company has also outperformed the Zacks Chemical - Specialty industry’s 9.1% growth over the same time frame. The rally has been supported by Ingevity’s successful portfolio optimization efforts, stronger demand for higher-value hybrid vehicle applications and pricing initiatives, which have improved earnings and boosted investor confidence in the company’s long-term growth prospects.
Image Source: Zacks Investment Research
Let’s take a look at the factors that are driving NGVT stock.
Portfolio Transformation & Higher Margins Support GrowthIngevity continues to benefit from its efforts to streamline and optimize its portfolio, with a focus on higher-margin businesses and enhancing the quality of its earnings. The company has made considerable progress in this strategy through the divestiture of its Industrial Specialties business, Ozark Materials Road Markings product line and crude tall oil refinery, while the Advanced Polymer Technologies business remains under the divestiture process. The sale of the Ozark Road Markings business for approximately $65 million strengthened the company’s portfolio.
Ingevity’s earnings are also supported by strategic acquisitions, including Georgia-Pacific’s pine chemicals business. Cost-reduction initiatives, pricing actions and favorable product mix have further aided profitability. These measures have helped the company mitigate inflationary pressures and maintain an impressive financial performance amid an uncertain macroeconomic backdrop.
In the second quarter, adjusted EBITDA climbed 14% year over year to $115 million, while adjusted EBITDA margin expanded to 36.6%. Management also raised its 2026 adjusted EBITDA guidance to $380-$400 million, reflecting confidence in the company’s earnings.
The company is also gaining from the increasing penetration of hybrid vehicles. As consumer preferences have shifted toward hybrids, particularly following the expiration of EV tax credits, demand for advanced and higher-value activated carbon solutions has improved. This trend, together with pricing actions and a favorable product mix, has supported sales and profitability in Performance Materials. Management expects the growing adoption of hybrids to develop into a broader global trend, offering lucrative growth potential in the future.
Overall, continued portfolio simplification, improving margins, pricing benefits and rising demand for higher-value applications should support Ingevity’s earnings growth and enhance long-term shareholder value.
NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) .
While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pegged at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 84.1% over the past year.
The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’s shares have gained 17.4% over the past year.
Ingevity zvýšila výhled upraveného EPS pro rok 2026 na 5 až 5,45 USD a výhled EBITDA na 380 až 400 milionů USD. Firma zároveň pokračuje v portfoliové transformaci a rozšiřuje nové růstové oblasti.
Key Takeaways Ingevity raised its 2026 adjusted EPS outlook to $5-$5.45 and EBITDA forecast to $380-$400 million.Portfolio divestitures and stranded-cost cuts are sharpening Ingevity's focus on higher-return opportunities.PFAS filtration, caprolactone and polyol expansion, and hybrid demand are opening new growth avenues. Ingevity Corporation (NGVT - Free Report) is benefiting from investments in high-return opportunities and development of new growth avenues.
We are positive about NGVT’s prospects and believe that the time is right for you to add the stock to the portfolio, as it looks promising and is poised to carry the momentum ahead.
Let's see what makes NGVT stock an attractive investment option at the moment.
Positive Analyst Sentiment for NGVT StockEarnings estimates for NGVT have been going up over the past 30 days. The Zacks Consensus Estimate for fiscal 2026 has increased by 6.9%. The consensus estimate for fiscal 2027 has also been revised 1.7% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.
The Zacks Consensus Estimate for NGVT’s 2026 earnings is pegged at $5.40, suggesting a 30.75% increase from the previous year’s tally. Earnings are projected to increase by 9.26% in 2027.
Image Source: Zacks Investment Research
NGVT’s Superior Return on Equity (ROE)ROE is a measure of a company’s efficiency in utilizing shareholders’ funds. ROE for the trailing 12-months for Ingevity is 284.7%, above the industry’s level of 22.1%.
Image Source: Zacks Investment Research
Upbeat OutlookIngevity raised its full-year 2026 adjusted earnings guidance to $5-$5.45 per share from the previous projection of $4.7-$5.2. The company also increased its adjusted EBITDA forecast to $380-$400 million from $370-$395 million. The company continues to expect full-year net sales of $1.05-$1.15 billion. Free cash flow is now projected at $220-$245 million, excluding the $113.2 million litigation settlement payment compared with the prior outlook of $215-$245 million.
An OutperformerIngevity shares have gained 20.3% against the industry’s decline of 0.9% in the past year.
Image Source: Zacks Investment Research
Portfolio Transformation and New Growth Platforms Support NGVTIngevity’s ongoing portfolio transformation is improving the prospects of its business and sharpening its focus on higher-return opportunities. The company has completed the divestitures of Industrial Specialties and Road Markings, while the divestiture process for Advanced Polymer Technologies is now progressing steadily. It has also eliminated $10 million of approximately $20 million in stranded costs associated with the divestitures, providing an additional structural cost benefit.
The company is also developing newer avenues that could support growth over time. Ingevity secured its first municipal water-treatment contract for PFAS filtration, a significant commercial validation. Its differentiated performance and lower-cost, drop-in potential of its carbon technology address PFAS requirements. The company is also expanding the monomer production capacity of caprolactone in Warrington and increasing the polyol capacity at its DeRidder plant.
Meanwhile, the structural shift toward hybrid vehicles is strengthening Ingevity’s Performance Materials segment. Hybrids require more advanced carbon solutions and generate a higher-value product mix, supporting the segment’s long-term competitive positioning.
Finally, disciplined capital allocation retains Ingevity’s lucrativeness. Leverage has reached 2.5X, while the company continues to reduce debt and invest in high-return opportunities. Ingevity repurchased $35 million of shares in the second quarter and remains committed to its $300 million repurchase program through 2027, providing an additional tailwind for the stock.
NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) .
While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 93% over the past year.
The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 19.6% over the past year.
Ingevity ve 2. čtvrtletí zvýšila upravený zisk na akcii o 42,6 % na 1,74 USD a tržby překonaly odhady na 314,1 mil. USD. Firma zároveň zvedla celoroční výhled upraveného EPS na 5–5,45 USD.
Key Takeaways Ingevity's Q2 adjusted EPS rose 42.6% to $1.74, while revenues beat estimates at $314.1 million.Pricing, product mix and higher volumes lifted adjusted EBITDA margin to 36.6% despite lower sales.Ingevity raised 2026 EPS guidance to $5-$5.45 and EBITDA guidance to $380-$400 million. Ingevity Corporation (NGVT - Free Report) reported second-quarter 2026 adjusted earnings of $1.74 per share, up 42.6% year over year and above the Zacks Consensus Estimate of $1.31 by 32.8%.
Revenues declined 5.2% to $314.1 million but surpassed the consensus mark of $299.4 million by 4.9%. Excluding the divested Road Markings business, sales rose 5%. Higher pricing, favorable product mix and increased volumes lifted adjusted EBITDA margin to 36.6%.
Segmental ReviewPerformance Materials generated net sales of $160.6 million, up 4.4% from $153.9 million in the prior-year quarter. The segment’s EBITDA increased 6.3% year over year to $86.1 million. Higher volumes, improved price and mix, and stronger plant utilization more than offset increased selling, general and administrative and other expenses.
The company’s Performance Chemicals operations are now represented by the Pavement Technologies segment following the Road Markings divestiture. Pavement Technologies’ net sales fell 22.4% year over year to $104.2 million, primarily because the Road Markings product line was sold on April 15, 2026. Segment EBITDA declined to $25.4 million from $28.8 million because the prior-year quarter included $6 million of Road Markings EBITDA. Improved pricing and volumes in the remaining business partly offset the lost contribution.
Advanced Polymer Technologies posted net sales of $49.3 million, up 13.9% from $43.3 million. Segment EBITDA jumped to $11.2 million from $2 million. Improved product mix and higher plant utilization supported the increase, as the year-ago period included extended downtime related to new boiler installations.
FinancialsNet cash used in operating activities was $13.8 million in the second quarter. Free cash flow totaled $89.1 million. NGVT repurchased approximately $35 million of common stock during the quarter at a weighted average price of $70.94 per share. Roughly $211 million remained available under the company’s existing share-repurchase authorization at the end of the period. Net leverage improved to 2.5 times from 3 times in the prior-year quarter and also declined from the first quarter of 2026. Cash and cash equivalents stood at $97.4 million as of June 30, 2026.
OutlookIngevity raised its full-year 2026 adjusted earnings guidance to $5-$5.45 per share from the previous projection of $4.7-$5.2. The company also increased its adjusted EBITDA forecast to $380-$400 million from $370-$395 million. The company continues to expect full-year net sales of $1.05-$1.15 billion. Free cash flow is now projected at $220-$245 million, excluding the $113.2 million litigation settlement payment, compared with the prior outlook of $215-$245 million. Ingevity intends to use its projected cash generation to reduce leverage to its long-term target range of 2-2.5 times and return capital to shareholders.
NGVT Stock’s Price PerformanceShares of Ingevity have gained 52.7% in a year compared with the industry’s 5.6% growth.
Image Source: Zacks Investment Research
NGVT’s Rank & Key PicksNGVT currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Neo Performance Materials Inc. (NOPMF - Free Report) ,Almonty Industries Inc. (ALM - Free Report) and Skeena Resources Limited (SKE - Free Report) .
Neo Performance is slated to report second-quarter 2026 results on Aug. 11. The Zacks Consensus Estimate for earnings is pegged at 50 cents per share. NOPMF sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Almonty is expected to report second-quarter 2026 results on Aug. 13. The Zacks Consensus Estimate for ALM’s second-quarter earnings per share is pegged at 10 cents, indicating 300% year-over-year growth. ALM carries a Zacks Rank #2 (Buy) at present.
Skeena is expected to report second-quarter 2026 results on Aug. 13. The consensus estimate for SKE’s loss per share is pegged at 11 cents. SKE presently carries a Zacks Rank #2.
Ingevity ve 2. čtvrtletí překonala odhady: EPS činil 1,74 USD a tržby 314,1 milionu USD. Firma zároveň zvýšila celoroční výhled upraveného EPS na 5,00 až 5,45 USD.
Bank of New York Mellon Corp reduced its stake in shares of Ingevity Corporation (NYSE:NGVT – Free Report) by 6.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,002 shares of the company’s stock after selling 13,808 shares during the quarter. Bank of New York Mellon Corp owned about 0.60% of Ingevity worth $15,030,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of NGVT. Global Retirement Partners LLC acquired a new stake in shares of Ingevity in the 4th quarter valued at $27,000. Meeder Asset Management Inc. acquired a new position in shares of Ingevity during the fourth quarter valued at $33,000. Kestra Advisory Services LLC bought a new position in Ingevity in the fourth quarter valued at about $47,000. Geneos Wealth Management Inc. increased its position in Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Ingevity in the second quarter worth about $46,000. Institutional investors own 91.59% of the company’s stock.
Ingevity Stock Performance Shares of NGVT stock opened at $70.02 on Friday. Ingevity Corporation has a 52 week low of $39.74 and a 52 week high of $79.29. The company has a debt-to-equity ratio of 27.83, a quick ratio of 0.92 and a current ratio of 1.42. The company’s 50 day moving average price is $71.63 and its two-hundred day moving average price is $70.95. The company has a market capitalization of $2.43 billion, a P/E ratio of 47.63 and a beta of 1.16.
Ingevity (NYSE:NGVT – Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 261.97% and a net margin of 4.65%.The firm had revenue of $314.10 million during the quarter, compared to analysts’ expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, analysts expect that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.
Insider Buying and Selling In other news, SVP Terrance M. Dyer sold 496 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.88% of the company’s stock.
Key Ingevity News Here are the key news stories impacting Ingevity this week:
Positive Sentiment: Quarterly earnings beat expectations. Ingevity reported second-quarter EPS of $1.74, above analyst estimates ranging from $1.31 to $1.33 and up from $1.39 a year earlier. Revenue of $314.1 million also exceeded the $312.2 million consensus estimate. Ingevity Tops Q2 Earnings and Revenue Estimates Positive Sentiment: Full-year 2026 adjusted EPS guidance was raised. The company now expects adjusted EPS of $5.00 to $5.45, above the prior outlook and higher than the roughly $4.95-$5.05 analyst consensus range. Ingevity also increased its full-year adjusted EBITDA outlook following a solid start to the year. Ingevity’s Q2 Adjusted Earnings Increase, Net Sales Decline; 2026 Adjusted EPS Outlook Raised Neutral Sentiment: Revenue guidance remains broadly in line with expectations. Ingevity maintained 2026 revenue guidance of approximately $1.1 billion to $1.2 billion, compared with consensus expectations near $1.1 billion. Ingevity Reports Second Quarter 2026 Financial Results Negative Sentiment: Net sales declined year over year. Although quarterly revenue edged past estimates, the year-over-year sales decline creates concern about underlying demand and may offset some of the benefit from stronger earnings guidance. The company also reported a negative net margin, adding to investor caution. Analyst Upgrades and Downgrades A number of research analysts have issued reports on NGVT shares. Wall Street Zen upgraded shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ingevity currently has a consensus rating of “Hold” and a consensus target price of $80.00.
Read Our Latest Stock Analysis on Ingevity
About Ingevity (Free Report)
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Read More Five stocks we like better than Ingevity Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEThe Kroger Co. $KR Shares Sold by First Trust Advisors LP
NEXT HEADLINE »First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVT
Ingevity (NGVT - Free Report) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.39 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +32.82%. A quarter ago, it was expected that this company would post earnings of $0.84 per share when it actually produced earnings of $1.15, delivering a surprise of +36.9%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Ingevity, which belongs to the Zacks Chemical - Specialty industry, posted revenues of $314.1 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.91%. This compares to year-ago revenues of $365.1 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ingevity shares have added about 25.9% since the beginning of the year versus the S&P 500's gain of 8.5%.
What's Next for Ingevity?While Ingevity has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ingevity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.64 on $304.7 million in revenues for the coming quarter and $5.05 on $1.12 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Specialty is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Linde (LIN - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on July 31.
This gas supplier is expected to post quarterly earnings of $4.49 per share in its upcoming report, which represents a year-over-year change of +9.8%. The consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level.
Linde's revenues are expected to be $8.96 billion, up 5.5% from the year-ago quarter.
Ingevity získala od BASt schválení pro Evotherm P35 k použití v teplé asfaltové směsi v Německu. Testy potvrdily odolnost a dlouhodobý výkon v reálných podmínkách.
Key Takeaways Ingevity's Evotherm P35 gained BASt approval for warm-mix asphalt use in Germany.Years of testing confirmed the product's durability and long-term performance under real-world conditions.Bio-based materials support performance and environmental goals in pavement applications. Ingevity Corporation (NGVT - Free Report) announced that its Evotherm P35 warm-mix additive has received approval from BASt, Germany's Federal Highway Research Institute, indicating that it meets the institute’s stringent quality standards. The approval allows the additive to be used in warm-mix asphalt applications and validates it for use in one of Europe's most demanding regulatory environments.
The approval follows several years of technical evaluation, performance testing and comparison with conventional hot-mix asphalt. The testing was conducted under real-world traffic and environmental conditions. The results met BASt's durability and long-term performance standards required for use on federal projects in Germany.
The certification strengthens Ingevity's position in the European pavement technologies market, where regulatory requirements for infrastructure materials are particularly demanding. It also demonstrates the company's ability to tailor its technologies to meet regional specifications while maintaining high performance standards. Evotherm P35 aligns with Germany's performance, environmental and regulatory priorities, highlighting the company’s formulation expertise and capability to satisfy complex technical requirements.
Evotherm P35 incorporates bio-based materials designed to improve performance while supporting environmental objectives, reinforcing the company's Pavement Technologies business.
NGVT’s shares have gained 62.8% over the past year compared with the industry’s 3.2% growth.
Image Source: Zacks Investment Research
NGVT’s Zacks Rank & Key PicksIngevity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Kronos Worldwide, Inc. (KRO - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Albemarle Corporation (ALB - Free Report) .
While KRO and CRS currently sport a Zacks Rank #1 (Strong Buy) each, ALB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for KRO’s 2026 loss is pinned at 33 cents per share, indicating a 65.63% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in one of the trailing four quarters and missed the remaining three. KROshares have gained 7.1% over the past year.
The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%.
The Zacks Consensus Estimate for ALB’s current fiscal-year earnings is pinned at $13.06 per share, indicating a 1,753% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have gained 55% over the past year.
Akcie Ingevity letos vzrostly o 24,8 % a překonaly 18,1% růst odvětví díky prodeji aktiv, akvizicím a vyšší poptávce po hybridech. Prodej Ozark Road Markings přinesl zhruba 65 mil. USD.
Key Takeaways Ingevity shares have surged 24.8% YTD, outperforming the specialty chemicals industry's 18.1% gain.NGVT is streamlining via divestitures, acquisitions and cost cuts to improve margins and earnings quality.NGVT benefits from hybrid demand, boosting activated carbon sales and Performance Materials growth. Ingevity Corporation (NGVT - Free Report) shares have rallied 24.8% year to date. The company has also outperformed the Zacks Chemical - Specialty industry’s 18.1% growth over the same time frame. The rally has been driven by Ingevity's successful portfolio optimization strategy, improving demand for higher-value hybrid vehicle applications and pricing actions that have strengthened earnings growth and reinforced confidence in the company’s long-term growth outlook.
Image Source: Zacks Investment Research
Let’s take a look at the factors that are driving NGVT stock.
Portfolio Optimization & Hybrid Vehicle Demand Drive GrowthIngevity is benefiting from its ongoing portfolio optimization and simplification strategy, which is aimed at sharpening its focus on higher-margin businesses and improving overall earnings quality. The company has made significant progress by divesting its Industrial Specialties business, Ozark Materials Road Markings product line and crude tall oil refinery, while continuing the divestiture process for its Advanced Polymer Technologies business. The company has recently completed the sale of its Ozark Road Markings business for approximately $65 million as part of these initiatives.
Additionally, value-creating acquisitions such as Georgia-Pacific’s pine chemicals business have driven earnings and revenue growth. The company has also undertaken actions to lower costs and boost profitability. The ability of NGVT to offset inflation through pricing power also enabled solid financial results despite an uncertain macroeconomic environment.
Alongside the portfolio transformation actions, Ingevity is benefiting from the adoption of hybrid vehicles. Following the expiration of EV tax credits, consumer preference has shifted toward hybrids, which has increased the long-term role of advanced and higher-value activated carbon solutions. This favorable product mix, combined with pricing actions, drove higher sales and stronger margins in Ingevity’s strongest segment, Performance Materials. Management also expects the transition toward hybrids to become a broader global trend, creating a long-term growth opportunity for its high-margin Performance Materials business.
Together, the company's strategic portfolio optimization and increasing exposure to higher-value hybrid vehicle applications position it for stronger earnings growth, improved profitability and sustainable shareholder value creation.
NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .
While ALB sports a Zacks Rank #1 (Strong Buy) at present, CRS and ASM carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.98 per share, indicating a 1,743.04% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed one, with an average surprise of 74.5%. ALB’s shares have jumped 90.5% over the past year.
The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%.
The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 34 cents per share, indicating a 17.24% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%. ASM’sshares have gained 86.4% over the past year.
